Skip to content
drillr.ai

CRNX

Crinetics Pharmaceuticals, Inc.

NASDAQ · USHealthcareBiotechnology
$83.87+0.01%

Price as of Jul 20, 2026

CRNX news

Crinetics Pharmaceuticals, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—ESI, CRNX, SOLS, and ALOT

    NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde (https://www.globenewswire.com/Tracker?data=acLo-qQu4Cl4Yz9sHsuWdcy916gw_igRzsvOFkboWEjuraUzcNqULL5G5-0C4HyjrbL1vHh0gni_lZH44y5wfSzlw6biG5VjrfA27an8s9ekxa4hyvmilbXxegy-3nbirRSEsVBwoOHyXnuhGaMxoHZfzJG3s12XgunPt4CEIprdbasegGpsNKX9HOK172vMUXv0ziQRkM_i_ATLLa9MZA==) with Monteverde & Associates PC (https://www.globenewswire.com/Tracker?data=5QLnV5ruDVgdQ4T2mRgmB5WOmv7Yc2MJRT4igYV7m6HazIlHgo06KWPqB3dEI0KPCjcezlokiAcsJx2

    Globe Newswire ·

  2. Halper Sadeh LLC is Investigating Whether TCBK, ESI, CRNX, SOLS are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Halpe

    Globe Newswire ·

  3. $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESI, CRNX, SOLS, and PATK

    $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESI, CRNX, SOLS, and PATK PR Newswire NEW YORK, July 16, 2026 NEW YORK, July 16, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733362-3&h=3726264568&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde)  with Monteverde & Associates PC (https://edge

    PR Newswire ·

  4. Halper Sadeh LLC is Investigating Whether ESI, CRNX, SOLS are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Halpe

    Globe Newswire ·

  5. $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—ESI, CRNX, SOLS, and PATK

    NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde (https://www.globenewswire.com/Tracker?data=DkVG55e-B1XNn1rFZsZCxdnATCtnOwYT8BpI0PpCPf4QTxIGVVQKpqzlZc8URzteWf42KQZt1-Dx-aEyu9TYBZWNRXNynfH6C1rQsrXDu8EEzZ4WAK-06y_zgPsFiZ2KBGdamwzdjwcF2Ixm9R7bCtoicgTbI5a57ThZeiTxUhh6xirm_qn-UugkSSi077Ygpbe-v1f6miSDHEFIPRIshQ==) with Monteverde & Associates PC (https://www.globenewswire.com/Tracker?data=ud-QoPemh7AHQtb0i5CyoZQXEGWb4G2WeeXVuMobvqcr0VA2S2TDho8qAMHIL9VzxQvSMv1VbzYm71O

    Globe Newswire ·

  6. Are CRNX, VEEE, ESI Obtaining Fair Deals for their Shareholders?

    Are CRNX, VEEE, ESI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 14, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for

    PR Newswire ·

  7. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)

    BALA CYNWYD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. TriCo Bancshares (Nasdaq – TCBK) Under the terms of the Merger Agreement, TriCo Bancshares will be acquired by First Hawaiian, Inc. (Nasdaq - FHB) in an all-sto

    Globe Newswire ·

  8. Are ESI, CRNX, SOLS Obtaining Fair Deals for their Shareholders?

    Are ESI, CRNX, SOLS Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 9, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for o

    PR Newswire ·

  9. $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)

    $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4728652-2&h=1427365213&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde)  with Monteverde & Associates PC (ht

    PR Newswire ·

  10. Halper Sadeh LLC is Investigating Whether CRNX, ESI, INVE, SLP are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Halpe

    Globe Newswire ·

  11. Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

    Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com%2F&esheet=54567265&newsitemid=20260708039070&lan=en-US&anchor=Kahn+Swick+%26+Foti&index=514&md5=dd76154236e9a044471cb4c477219f66) , LLC (“KSF”) a

    Business Wire ·

  12. CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transaction may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Halper

    Globe Newswire ·

  13. SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)

    Bala Cynwyd, Pennsylvania--(Newsfile Corp. - July 7, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Crinetics Pharmaceuticals, Inc. ("Crinetics Pharmaceuticals" or the "Company") (NASDAQ: CRNX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $85.00 per share in cash, for a total equi

    Newsfile Corp ·

  14. Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

    Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders PR Newswire MILWAUKEE, July 6, 2026 MILWAUKEE, July 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex. Click here (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4726207-1&h=87675889&u=https%3A%2F%2Fwww.ademilaw.com%2Fca

    PR Newswire ·

  15. Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

    SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (https://www.globenewswire.com/Tracker?data=okJmZilJTOilP5DHDEnDC4oJHvNHHsLgyiLak85EU8uNkB5RoV2-jQGBNTrHdaCDcTODQ_bVoqutAxHQm00C60jCR3-iwIXeAvMyYKGH87KLQz1WTNG0trFAeVZAH7dxEX9bTpwiVASr-_be9cYNeQ==) (Nasdaq: CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial

    Globe Newswire ·

  16. Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

    Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New results from the Phase 1b/2a ACTH-dependent Cushing’s syndrome trial also presented, showing atumelnant rapidly lowered early morning cortisol and normalized urinary free cortisol levels even at lower dose SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (https://www.globene

    Globe Newswire ·

  17. Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

    Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or reduced pituitary tumor volumes for up to 48 weeks Additional ENDO highlights include long-term ACROBAT data demonstrating PALSONIFY and cabergoline combination improves biochemical control of acromegaly SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (https://www.glob

    Globe Newswire ·

  18. Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

    Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee of five leading patient organizations to guide program with authentic perspectives and insights into most significant patient needs SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (https://www.globenewswire.com/Tracker?data=kEHQRDxI0IDBeK9pHKWDMuSKXSe7pnuyPA6haWug3SEX

    Globe Newswire ·

  19. Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

    Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals  Two oral presentations of novel, investigational ACTH receptor antagonist atumelnant include full Phase 2 study results in congenital adrenal hyperplasia and data from additional patients in the Phase 1b/2a ACTH-dependent Cushing’s syndrome study SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.

    Globe Newswire ·

  20. Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

    SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (https://www.globenewswire.com/Tracker?data=HszNnSVHGtY5I2lIFiuBz5C1ZClazId5uXgEmkrqar4PZY6n1muyLVPkTqH8zexado2Skz_rkz_BGXag5A6bvVqo2t9FwCc3IIaYWNdTScI=) (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY.   Management will be available for 1x1 meetings with investors on Wednesday, June 3, 2026. If you are in

    Globe Newswire ·